RxDoctor Payments Data

Sarah Doss, MD

Neurology · Kearney, NENPI 1215599311

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (42.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 39.2% of the total.

$9,521in general payments, 2019–2025

Across 136 payments — averaging $70.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$2K
  • Biogen$2K
  • AbbVie$1K
  • Argenx US, Inc.$248
  • EMD Serono, Inc.$243
  • plus $989 from 16 others

What the payments were for

  • Consulting fees$1,34514%
  • Travel & lodging$4,08543%
  • Food & beverage$3,99842%
  • Education$941%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,521 in reported general payments places this provider in the 85th percentile of 105 neurology providers in Nebraska.

See all neurology providers in Nebraska

Medicare billing

Part B allowed, 2024
$97,404
Medicare patients
369
Services billed
1,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone25$780,184
IngrezzaValbenazine Tosylate13$102,935
RytaryCarbidopa/Levodopa73$80,357
Carbidopa-LevodopaCarbidopa/Levodopa648$24,861
Nurtec OdtRimegepant Sulfate20$24,834
QuliptaAtogepant20$23,167
UbrelvyUbrogepant21$22,853
AmantadineAmantadine Hcl147$7,172
Memantine Hcl246$5,979
Carbidopa-Levodopa ErCarbidopa/Levodopa143$5,564
Dalfampridine ErDalfampridine25$4,988
Gabapentin305$4,676
Donepezil Hcl317$3,983
Levetiracetam120$3,579
Carbamazepine ErCarbamazepine18$2,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$1,507$780,18425 claims
Neurocrine Biosciences, Inc.Ingrezza$193$102,93513 claims
Amneal Pharmaceuticals LLCRytary$17$80,35773 claims
AbbVieQulipta, Ubrelvy$1,180$46,01941 claims
PfizerNurtec Odt$14$24,83420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 neurology providers in Nebraska.

Other neurology in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →